Theravance Biopharma Inc. (TBPH) Trading Up 3%
Theravance Biopharma Inc. (NASDAQ:TBPH) was up 3% on Friday . The stock traded as high as $26.74 and last traded at $26.74, with a volume of 291,619 shares trading hands. The stock had previously closed at $25.96.
Several equities research analysts have recently weighed in on TBPH shares. Leerink Swann reissued a “buy” rating and issued a $31.00 price objective on shares of Theravance Biopharma in a report on Tuesday, August 9th. Guggenheim started coverage on Theravance Biopharma in a report on Monday, June 20th. They issued a “buy” rating and a $30.00 price objective for the company. Zacks Investment Research raised Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a report on Tuesday, July 12th. Finally, Bank of America Corp. downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Thursday, May 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $29.00.
The firm has a 50 day moving average of $23.89 and a 200 day moving average of $20.56. The company’s market capitalization is $1.29 billion.
Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.01. On average, analysts anticipate that Theravance Biopharma Inc. will post ($4.03) EPS for the current year.
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.